Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

February 15, 2022

Study Completion Date

June 15, 2022

Conditions
CarcinomaOvarian NeoplasmEndocrine Gland NeoplasmUrogenital NeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsEndocrine System DiseasesGonadal DisordersGenital Neoplasm, FemaleNeoplasms, Glandular and Epithelial
Interventions
DIETARY_SUPPLEMENT

Ocoxin-Viusid

Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).

Trial Locations (1)

10400

National Institute of Oncology and Radiobiology (INOR), Havana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | Biotech Hunter | Biotech Hunter